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OBJECTIVES: Clinical practice guidelines suggest that to achieve greater reductions 
in cardiovascular risk, statin therapy should be prescribed for diabetic patients at 
earlier stages. The objective of this study was to assess the inﬂuence of statin therapy 
on diabetes-speciﬁc hospitalization and all-cause mortality in diabetic patients enrolled 
in a state Medicaid program. METHODS: This is a retrospective cohort study of 
patients with diabetes using Medicaid pharmacy and medical claims data. Patients 
aged 40 years or older with a diagnosis of diabetes, who had continuous coverage in 
a state Medicaid program from January 2002 to December 2004, and who had a 
diagnosis of diabetes in 2002 were included in the study and were followed up until 
December 2004. Statin therapy was measured in using pharmacy claims data of 2003 
and statin use was deﬁned as at least two ﬁlled prescriptions for statin medications in 
2003. The primary outcomes of interest were diabetes-speciﬁc hospitalization and 
all-cause mortality in 2004. Multivariate regression analyses were performed to assess 
the impact of statin therapy on outcome measures. RESULTS: A total of 21,110 
patients met our inclusion criteria. Among them, 76.6% were females and the mean 
age was 62.9 (± 12.3) years. Less than 30% (28.7%) were prescribed statin medica-
tions in 2003. After controlling for baseline patient characteristics including age, 
gender, race, prior hospitalization, comorbidities (measured using Charlson comorbid-
ity index), and use of insulin, oral hypoglycemic agents, and antihypertensive medica-
tions, in comparison to non-users, statin users were 29.1% less likely to have 
diabetes-speciﬁc hospitalizations (OR: 0.719; 95%CI: 0.628–0.824). The odds for 
all-cause mortality were also lower in statin users as compared to non-users (OR: 
0.480; 95%CI: 0.327–0.705). CONCLUSIONS: The results of this study show that 
statin use rate is low among adults enrolled in a Medicaid program. Statin therapy 
in adult diabetic patients reduces diabetes-speciﬁc hospitalizations and all-cause 
mortality.
DIABETES/ENDOCRINE DISORDERS – Conceptual Papers & Research  
on Methods
PDB76
AN OPEN-SOURCE, INTERACTIVE MODEL TO ASSESS THE OUTCOMES 
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OBJECTIVES: Several decision-theoretic models exist to assess the long-term out-
comes and economics of diabetic interventions. Since the models are proprietary, users 
are limited in their ability to critically review program code and modify inputs for 
their speciﬁc setting. The main objective was to develop a diabetes model with open-
source code that is unlocked, transparent, and modiﬁable by users, which are impor-
tant considerations for pharmaceutical decision makers, particularly in Canada. 
METHODS: The analytical framework is similar to the United Kingdom Prospective 
Diabetes Study (UKPDS)-based model (Clarke et al., Diabetologia 2004), and is 
created in Microsoft Excel, using visual basic. It is adaptable to both individual- and 
cohort-level data. Relationships between outcomes (e.g., myocardial infarction) and 
exogenous variables (e.g., HbA1c) were based on the equations as reported by Clark 
et al. The model was further modiﬁed to include (1) costs and disutilities associated 
with hypoglycemia and (2) options for emerging treatment intensiﬁcation regimens as 
the patient’s diabetes progresses. The model uses Canadian resource use data as 
defaults. The model was validated against the ﬁndings of the Ontario Diabetes Eco-
nomic Model (ODEM, http://www.path-hta.ca/diabetes.pdf, 2006). RESULTS: The 
quality-adjusted life-year gain of 8.23 for the control arm in published results of 
ODEM fell within the 95% conﬁdence interval of (8.20, 8.29) generated by the model. 
The corresponding results for life-years gained are also concordant. Unlike previous 
diabetes models, our model fulﬁlls Canadian drug submission requirements, speciﬁ-
cally the strict guidelines of the Common Drug Review (CDR) agency. CONCLU-
SIONS: An open-source, interactive diabetes model will greatly facilitate users’ 
– speciﬁcally clinicians and other decision makers – ability to modify inputs speciﬁc 
to their setting and rigorously assess the validity of ﬁndings.
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OBJECTIVES: This paper used data from an ongoing Merck sponsored study evaluat-
ing the effectiveness of diabetes self management education (DSME): Journey for 
Control of Diabetes: the IDEA Study. During enrollment visits, patients with sub-
optimally controlled Type 2 diabetes (A1c < 7%) completed surveys with 19 attitudi-
nal and behavioral scales; clinical measures were also obtained. Although the primary 
outcome for DSME evaluation was A1c, we included the attitudinal/ behavioral survey 
to identify intervening variables. Our goal was to identify a set of underlying factors 
to efﬁciently explain attitudes and clinical outcomes. METHODS: A total of 623 
patients were enrolled from 2 sites, Minnesota and New Mexico. The baseline survey 
included the following instruments: general health (SF-12); depression (PHQ-9); Dia-
betes Empowerment (DES-SF); diabetes attitudes (DCP, 5 scales); personality (TIPI); 
Problem Areas in Diabetes (PAID); diet (RFS); physical activity (BRFSS); Readiness 
to Change; and hypoglycemia and hyperglycemia events (self-report). Several clinical 
measurements were also obtained (BMI, waist circumference, and A1c level). Data 
from the above sample were used to conduct a factor analysis. RESULTS: Factor 
analysis was performed using varimax orthogonal rotation using the survey and clini-
cal variables. Five factors were identiﬁed for the sample of 588 patients with measures 
on all variables. The ﬁrst factor related to “agreeable” personality characteristics from 
the TIPI; the second and fourth factors both related to poor physical health with the 
second factor including those items relating to empowerment and low A1c while the 
fourth factor included extroversion, low activity levels, and increased glycemic events. 
Factor three was high weight and waist circumference as well as low activity levels, 
and factor ﬁve was primarily readiness to change. Communality scores ranged from 
.317 to .829. CONCLUSIONS: Factor analysis can help explain underlying factors 
affecting patients with diabetes. Future analyses will use these factor scores to predict 
the effectiveness of DSME.
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RANDOMIZED CLINICAL TRIAL (RCT) DESIGN AND ANALYTIC ISSUES 
IMPACTING ASSUMED CLINICAL EFFECTS AND RESULTS OF 
COST-EFFECTIVENESS ANALYSES: ILLUSTRATION FROM A RECENT 
CANADIAN REPORT ON THE COST-EFFECTIVENESS OF BLOOD 
GLUCOSE TEST STRIPS FOR TYPE 2 DIABETES
Tunis S
IMS Health Inc., Falls Church, VA, USA
Most cost-effectiveness analyses of interventions in type 2 diabetes mellitus (T2DM) 
are based on clinical effects from randomized clinical trials (RCTs). While RCTs are 
conducted to minimize certain types of bias, protocol design and analytic approach 
can minimize the magnitude of treatment effect and thus, degree of projected long-term 
cost-effectiveness. The goal of this review was to provide a methodological critique 
of trials used in a recent report by The Canadian Optimal Medication Prescribing and 
Utilization Service (COMPUS) on the cost-effectiveness of blood glucose test strips for 
T2DM patients, and to discuss speciﬁc factors impacting input assumptions and model 
results. Seven RCTs were included in the COMPUS meta-analysis of non-insulin 
treated T2DM patients (n = 2,270). Assuming 1.29 strips/day and a weighted mean 
HbA1c effect of −0.25%, the base case incremental cost-utility ratio was $CAN 
113,643/QALY. Source trials varied widely in terms of patients’ ability to act upon 
monitoring results, and required and actual monitoring frequency. Several character-
istics of the trial most-heavily weighted in the COMPUS analysis illustrate how 
potential effects of monitoring may be obscured. The standardized protocol did not 
allow patients to obtain monitoring feedback and discuss it with health care providers 
in a timely fashion. Although assessed through intent-to-treat analyses, approximately 
half of HbA1c endpoint data attributed to the “intensive” monitoring group was 
provided by patients who had not been monitoring for an extended period. In contrast, 
strip costs used as model inputs were “maximized” by assuming 100% protocol 
adherence. Cost-effectiveness analyses of T2DM interventions can beneﬁt from a 
careful review of RCT design and analytic issues that may serve to underestimate 
clinical effects. Studies assessing the clinical value of monitoring should include pro-
tocols that optimize patients’ ability to act upon results, as well as analyses that link 
assumed clinical effects to actual monitoring frequency.
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OBJECTIVES: To determine the association of gastrointestinal (GI) bleed over one 
year in a cohort of Medicare/Medicaid dual eligibles (Duals) taking warfarin alone or 
warfarin & non-steroidal anti-inﬂammatory drugs (NSAIDS) and determine the 
annual health care costs for patients with GI bleed versus no GI Bleed. METHODS: 
Data were obtained from Arizona State Medicaid Agency from January 1, 2005 
through December 31, 2005. Inclusion criteria consisted of Duals ³65 and <90 years 
of age with at least two claims for warfarin. Duals were grouped as taking warfarin 
alone or warfarin plus NSAID. Factors examines included age, sex, race/ethnicity 
membership, rural or urban residence, with adjustment for total number of prescrip-
tion claims and comorbidities. Analysis was performed utilizing a logistic regression 
model to determine odds of GI bleed when taking warfarin compared to warfarin plus 
NSAID. RESULTS: A total of 2916 patients met inclusion/exclusion criteria: 2538 
taking warfarin alone and 378 taking warfarin plus NSAID. Males comprised 771 
(30.4%) of warfarin and 88 (23.3%) of warfarin plus NSAID groups. Mean age (SD) 
was 76.6 (6.8) and 74.0 (6.1) in the warfarin and warfarin plus NSAID groups 
respectively. There were 126 (5.0%) GI bleed events in the warfarin and 29 (7.7%) 
events in the warfarin plus NSAID groups (p = 0.02). The odds ratio for GI bleed was 
1.51 (0.98–2.33). Mean total annual health care costs (SD) were $13,232 (15,476) in 
